Skip to main content
Top

29-04-2024 | Cardiomyopathy | Editor's Choice | News

ACC 2024

Ninerafaxstat shows early promise for treating nonobstructive hypertrophic cardiomyopathy

Author: Dr. Jonathan Smith

medwireNews: The cardiac mitotrope ninerafaxstat is well tolerated by patients with nonobstructive hypertrophic cardiomyopathy (nHCM), with early signs of improvements in exercise capacity and health status, a phase 2 trial suggests.

Related topics

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

Keynote webinar | Spotlight on medication adherence

  • Webinar | 27-06-2024 | 18:00 (CEST)

Medication non-adherence is a major barrier to effective healthcare delivery; half of all patients do not follow their doctor’s recommendations or treatment plan.

Our experts explain the fundamentals with a practical discussion of how to manage non-adherence in two common scenarios: hypertension and asthma control.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Watch now